VA Disability Rating for Visceral Leishmaniasis (DC 6301)

Diagnostic Code 6301 · 38 CFR §4.88b

What Is It?

Visceral leishmaniasis, also known as kala-azar, is a parasitic disease transmitted by sandfly bites. Veterans who served in the Middle East, Central Asia, or other tropical regions are at risk. The disease attacks internal organs, especially the spleen, liver, and bone marrow. The VA rates active disease at 100 percent with a mandatory re-examination six months after treatment ends. Residual organ damage such as liver disease and bone marrow problems is rated under the appropriate body system. Recurrence must be confirmed by culture, histopathology, or other diagnostic testing.

Rating Criteria

RatingCriteria
100%Active visceral leishmaniasis during treatment. The 100 percent rating continues through treatment and for six months after, followed by a mandatory VA examination.
0%Successfully treated with no residual organ damage. Residuals including liver damage and bone marrow disease are rated under the appropriate body system.

Evidence Needed

Lab results confirming Leishmania infection (serology, biopsy, or PCR). Deployment records to endemic regions. Treatment records. Follow-up labs monitoring for relapse. Documentation of residual organ damage.

Frequently Asked Questions

Can leishmaniasis reactivate years after treatment?

Yes, the parasite can remain dormant and reactivate, especially if the immune system becomes weakened. Follow-up monitoring is important.

Which deployment areas have the highest risk?

Iraq, Afghanistan, and other parts of the Middle East and Central Asia have significant sandfly populations carrying Leishmania.